PT2640842T - Métodos e composições para induzir uma resposta imune a egfrviii - Google Patents

Métodos e composições para induzir uma resposta imune a egfrviii

Info

Publication number
PT2640842T
PT2640842T PT11841347T PT11841347T PT2640842T PT 2640842 T PT2640842 T PT 2640842T PT 11841347 T PT11841347 T PT 11841347T PT 11841347 T PT11841347 T PT 11841347T PT 2640842 T PT2640842 T PT 2640842T
Authority
PT
Portugal
Prior art keywords
egfrviii
inducing
compositions
methods
immune response
Prior art date
Application number
PT11841347T
Other languages
English (en)
Portuguese (pt)
Inventor
M Lauer Peter
Bahjat Keith
Original Assignee
Providence Health & Services Oregon D/B/A Providence Portland Medical Center
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Providence Health & Services Oregon D/B/A Providence Portland Medical Center, Aduro Biotech Inc filed Critical Providence Health & Services Oregon D/B/A Providence Portland Medical Center
Publication of PT2640842T publication Critical patent/PT2640842T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT11841347T 2010-11-17 2011-11-17 Métodos e composições para induzir uma resposta imune a egfrviii PT2640842T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41485010P 2010-11-17 2010-11-17

Publications (1)

Publication Number Publication Date
PT2640842T true PT2640842T (pt) 2018-10-12

Family

ID=46084412

Family Applications (1)

Application Number Title Priority Date Filing Date
PT11841347T PT2640842T (pt) 2010-11-17 2011-11-17 Métodos e composições para induzir uma resposta imune a egfrviii

Country Status (17)

Country Link
US (3) US9200057B2 (OSRAM)
EP (1) EP2640842B1 (OSRAM)
JP (1) JP5998370B2 (OSRAM)
CN (1) CN103415620B (OSRAM)
CA (1) CA2818353A1 (OSRAM)
CY (1) CY1120622T1 (OSRAM)
DK (1) DK2640842T3 (OSRAM)
ES (1) ES2684684T3 (OSRAM)
HR (1) HRP20181343T1 (OSRAM)
HU (1) HUE039747T2 (OSRAM)
LT (1) LT2640842T (OSRAM)
PL (1) PL2640842T3 (OSRAM)
PT (1) PT2640842T (OSRAM)
RS (1) RS57630B1 (OSRAM)
SI (1) SI2640842T1 (OSRAM)
SM (1) SMT201800444T1 (OSRAM)
WO (1) WO2012068360A1 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
SI2640842T1 (sl) * 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
SG11201407875UA (en) 2012-06-08 2014-12-30 Aduro Biotech Compostions and methods for cancer immunotherapy
US9511129B2 (en) 2012-11-06 2016-12-06 Aduro Biotech, Inc. Facultatively attenuated bacterial species and methods of preparation and use thereof
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
MX2015008329A (es) 2012-12-27 2016-03-01 Aduro Biotech Inc Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
DK2996473T3 (da) 2013-05-18 2019-11-04 Aduro Biotech Inc Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
US10258679B2 (en) * 2014-04-24 2019-04-16 Advaxis, Inc. Recombinant Listeria vaccine strains and methods of producing the same
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
JP2017532328A (ja) * 2014-10-14 2017-11-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌治療用の併用療法
US10688166B2 (en) 2014-11-03 2020-06-23 Cerus Corporation Compositions and methods for improved car-T cell therapies
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
AU2016247887A1 (en) * 2015-04-13 2017-11-02 Aduro Biotech, Inc. Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same
MA44378A (fr) * 2015-04-13 2019-01-23 Aduro Biotech Inc Protéines de fusion immunogènes pour le traitement du cancer
US10455265B2 (en) * 2015-04-27 2019-10-22 Ericsson Ab Program and device class entitlements in a media platform
JP2018515588A (ja) * 2015-05-26 2018-06-14 アドバクシス， インコーポレイテッド 個別化送達ベクターに基づく免疫療法とその使用
MA42263A (fr) * 2015-06-24 2021-03-31 Advaxis Inc Dispositif de fabrication et procédé pour immunothérapie fondée sur un vecteur d'administration personnalisé
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018026717A1 (en) * 2016-08-01 2018-02-08 Aduro Biotech, Inc. Protein expression enhancer sequences and use thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
AU2018348165B2 (en) 2017-10-10 2025-09-04 Seattle Project Corp. Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
WO2021014398A1 (en) * 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
ATE262586T1 (de) * 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
WO2002097044A2 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
EP1513924A4 (en) 2002-05-29 2008-05-21 Univ California ATTENUATED LISTERIA SPP. AND METHOD OF USE THEREOF
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
MX2008005640A (es) * 2005-11-02 2008-12-09 Univ Duke Quimioterapia e inmunoterapia concurrentes.
JP5347135B2 (ja) * 2006-03-01 2013-11-20 アドゥロ バイオテック 遺伝子工学操作されたｌｉｓｔｅｒｉａおよびその使用方法
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US8900816B2 (en) * 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
EP2283112B1 (en) 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
AU2009273949A1 (en) * 2008-07-24 2010-01-28 Aduro Biotech Compositions and methods for the treatment of hepatitis C
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
SI2640842T1 (sl) * 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII

Also Published As

Publication number Publication date
CN103415620B (zh) 2016-10-12
SI2640842T1 (sl) 2018-09-28
US20140037662A1 (en) 2014-02-06
US20160074491A1 (en) 2016-03-17
CY1120622T1 (el) 2019-12-11
LT2640842T (lt) 2018-09-10
PL2640842T3 (pl) 2018-11-30
US20180021420A1 (en) 2018-01-25
RS57630B1 (sr) 2018-11-30
EP2640842A1 (en) 2013-09-25
CA2818353A1 (en) 2012-05-24
EP2640842B1 (en) 2018-05-30
US9200057B2 (en) 2015-12-01
HRP20181343T1 (hr) 2018-10-19
US9775891B2 (en) 2017-10-03
JP2014504851A (ja) 2014-02-27
DK2640842T3 (en) 2018-08-13
EP2640842A4 (en) 2014-04-09
JP5998370B2 (ja) 2016-09-28
HUE039747T2 (hu) 2019-02-28
CN103415620A (zh) 2013-11-27
ES2684684T3 (es) 2018-10-04
WO2012068360A1 (en) 2012-05-24
SMT201800444T1 (it) 2018-09-13

Similar Documents

Publication Publication Date Title
LT2640842T (lt) Būdai ir kompozicijos, skirti indukuoti imuninį atsaką į egfrviii
HRP20190368T1 (hr) Derivati arilmetoksi izoindolina i pripravci koji ih sadrže te postupci njihove uporabe
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
ZA201307919B (en) Composition and method for enhancing an immune response
ZA201402734B (en) Collector compositions and methods of using the same
IL224390B (en) Compositions and methods for targeted thermal modulation
PL3366143T3 (pl) Kompozycje probiotyczne i sposoby
PH12013500698A1 (en) Hair-mending compositions and associated methods
EP2637691A4 (en) MATERIALS AND METHOD FOR CONTROLLING AN IMMUNE RESPONSE TO AN EPITOP
EP2598120A4 (en) COMPOSITIONS AND METHOD FOR CREATING AN IMMUNO TOLERANCE
EP2680837A4 (en) COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE
GB201113770D0 (en) Novel compositions and uses thereof
IL234695A0 (en) Antigen compositions and methods
GB201018650D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
IL233873A (en) Methods for soaking up immune tolerance to organ transplants
GB201116340D0 (en) Compositions and methods
GB201018651D0 (en) Methods and compositions
GB201009767D0 (en) Compositions and methods
GB201010083D0 (en) Compositions and methods
GB201003741D0 (en) Methods and therapeutic compositions